左西替利嗪联合地氯雷他定治疗慢性荨麻疹80例临床观察

发布时间：2018-07-03 08:25

本文选题：慢性荨麻疹 + 地氯雷他定　；参考：《中国皮肤性病学杂志》2017年05期

【摘要】：目的评价左西替利嗪联合地氯雷他定治疗慢性荨麻疹的临床疗效及安全性。方法将入选的240例慢性荨麻疹患者随机分为3组,对照1组(80例)予左西替利嗪口服,对照2组(80例)予地氯雷他定口服,治疗组(80例)第一天予左西替利嗪口服,第二天予地氯雷他定口服,每天交替应用,疗程均为18个月。结果治疗1和3个月时治疗组患者依从性明显高于两个对照组(P=0.019,0.013)。在治疗3个月时治疗组疗效明显优于两对照组(P=0.001),在6到18个月三组依从性及疗效差异均没有统计学意义(P均0.05)。三组患者不良反应率均低且差异无统计学意义(P0.05)。结论左西替利嗪联合地氯雷他定治疗慢性荨麻疹近期疗效好,患者依从性高,远期疗效及依从性与两个药物单独治疗并无差异性,不良反应少,值得临床医生选择。
[Abstract]:Objective to evaluate the efficacy and safety of levatirizine combined with desloratadine in the treatment of chronic urticaria. Methods 240 patients with chronic urticaria were randomly divided into three groups: control group (n = 80), control group (n = 80) and control group (n = 80). Desloratadine was administered orally on the second day, alternately daily for 18 months. Results the compliance of the patients in the treatment group was significantly higher than that in the two control groups at 1 and 3 months after treatment (P0. 019 卤0. 013). The curative effect of the treatment group was significantly better than that of the control group at 3 months (P0. 001), but there was no significant difference in compliance and curative effect among the three groups at 6 to 18 months (P 0.05). The adverse reaction rate of the three groups was low and the difference was not statistically significant (P0.05). Conclusion Levcetirizine combined with desloratadine in the treatment of chronic urticaria has good short-term curative effect, high compliance, no difference in long-term effect and compliance with the two drugs alone, and less adverse reactions, which is worthy of choice by clinicians.
【作者单位】：广安市人民医院皮肤科;
【分类号】：R758.24

【参考文献】